Table 1.
Patient Characteristics at Baseline by Study and Intervention Sequence
| Study A | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Group 1 | Group 2 | Study B | |||||||
| Characteristic | A‐B (n = 6) | B‐A (n = 6) | Total (n = 12) | A‐C (n = 12) | C‐A (n = 12) | Total (n = 24) | D‐E (n = 18) | E‐D (n = 18) | Total (n = 36) |
| Women, n (%) | 6 (100) | 6 (100) | 12 (100) | 7 (58.3) | 9 (75.0) | 16 (66.7) | 16 (88.9) | 16 (88.9) | 32 (88.9) |
| Age, yearsa | 33.3 (22‐42) | 34.3 (27‐39) | 33.8 (22‐42) | 32.5 (18‐44) | 32.3 (22‐45) | 32.4 (18‐45) | 34.3 (27–45) | 33.6 (26–43) | 33.9 (26–45) |
| Weight, kg | 62.9 ± 4.4 | 66.8 ± 12.5 | 64.9 ± 9.2 | 64.5 ± 14.7 | 63.3 ± 11.4 | 63.9 ± 12.9 | 63.6 ± 10.7 | 65.3 ± 10.9 | 64.4 ± 10.7 |
| BMI, kg/m2 | 25.8 ± 2.8 | 26.3 ± 2.5 | 26.1 ± 2.5 | 24.6 ± 3.4 | 24.2 ± 3.2 | 24.4 ± 3.2 | 25.7 ± 3.5 | 26.9 ± 2.6 | 26.3 ± 3.1 |
BMI, body mass index.
Study A: intervention A, 4 × 30‐mg tablets; intervention B, 4 × 30 mg aqueous slurry; intervention C, 1 × 120‐mg tablet (all dosing was under fed conditions). Study B: intervention D, 4 × 30‐mg tablets, fasted; intervention E, 4 × 30‐mg tablets, fed.
a
Mean (range); other data are mean ± standard deviation unless stated otherwise.